<?xml version="1.0" encoding="UTF-8" standalone="no"?><rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" version="2.0">

<channel>
	<title>Medicare reports, fact sheets and explainers from the Kaiser Family Foundation</title>
	<atom:link href="https://www.kff.org/topic/medicare/feed/" rel="self" type="application/rss+xml"/>
	<link>https://www.kff.org/topic/medicare/</link>
	<description></description>
	<lastBuildDate>Fri, 24 Apr 2026 03:09:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.5</generator>

<image>
	<url>https://www.kff.org/wp-content/uploads/sites/7/2023/04/3976_KFF_favicon_256x256_revised.png?w=32</url>
	<title>Medicare - Research and Data from KFF</title>
	<link>https://www.kff.org/topic/medicare/</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">243654493</site>	<item>
		<title>CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage</title>
		<link>https://www.kff.org/quick-take/cms-extends-medicares-short-term-bridge-program-for-glp-1-obesity-drug-coverage/</link>
		
		<dc:creator><![CDATA[kffaeronw]]></dc:creator>
		<pubDate>Thu, 23 Apr 2026 18:42:29 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Federal Budget]]></category>
		<category><![CDATA[Prices]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=quick-take&amp;p=707142</guid>

					<description><![CDATA[Extending the short-term GLP-1 Bridge program is good news for eligible Medicare beneficiaries because it provides the certainty of obesity drug coverage at a $50 copay for a longer duration, but federal spending will also rise by some unknown amount since CMS hasn’t disclosed the projected cost.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">707142</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260423_Quick-Takes_Juliette-Cubanski_Website.jpg?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260423_Quick-Takes_Juliette-Cubanski_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260423_Quick-Takes_Juliette-Cubanski_Website.jpg?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Medicare Beneficiaries Enrolled in Part D Coverage</title>
		<link>https://www.kff.org/medicare/state-indicator/medicare-beneficiaries-enrolled-in-part-d-coverage/</link>
		
		<dc:creator><![CDATA[kffnatalies]]></dc:creator>
		<pubDate>Fri, 10 Apr 2026 13:19:20 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<guid isPermaLink="false"/>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">488230</post-id>
	</item>
		<item>
		<title>Number of Medicare Stand-alone Prescription Drug Plans (PDPs)</title>
		<link>https://www.kff.org/medicare/state-indicator/prescription-drug-plans-pdps/</link>
		
		<dc:creator/>
		<pubDate>Fri, 10 Apr 2026 13:02:20 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<guid isPermaLink="false"/>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">65295</post-id>
	</item>
		<item>
		<title>Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update</title>
		<link>https://www.kff.org/quick-take/medicare-advantage-insurers-will-see-higher-payments-as-cms-backs-off-a-key-payment-update/</link>
		
		<dc:creator><![CDATA[kffcarenec]]></dc:creator>
		<pubDate>Wed, 08 Apr 2026 14:54:03 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Benefits]]></category>
		<category><![CDATA[Enrollment]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Premiums]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=quick-take&amp;p=706299</guid>

					<description><![CDATA[The Trump administration this week backed off a key element of its Medicare Advantage rate proposal, resulting in billions of dollars in additional payments to private insurers. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">706299</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260408_QuickTakes_Jeannie-Fuglesten-Biniek_Website.jpg?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260408_QuickTakes_Jeannie-Fuglesten-Biniek_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260408_QuickTakes_Jeannie-Fuglesten-Biniek_Website.jpg?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied</title>
		<link>https://www.kff.org/quick-take/insurers-prior-authorization-data-offers-little-insight-into-what-gets-approved-or-denied/</link>
		
		<dc:creator><![CDATA[kffcarenec]]></dc:creator>
		<pubDate>Thu, 02 Apr 2026 13:30:27 +0000</pubDate>
				<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[ACA Marketplaces]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Prior Authorization]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[Certain insurers must now publicly report specific prior authorization metrics, but the new data offer limited insight, providing no information on what types of services are being approved and denied or why as well as no data on prescription drugs. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">706045</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260402_QuickTakes_Kaye-Pestaina_Website-1.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260402_QuickTakes_Kaye-Pestaina_Website 1</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260402_QuickTakes_Kaye-Pestaina_Website-1.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>The New Ideas Conundrum in Health Policy</title>
		<link>https://www.kff.org/from-drew-altman/the-new-ideas-conundrum-in-health-policy/</link>
		
		<dc:creator><![CDATA[kfftammies]]></dc:creator>
		<pubDate>Wed, 01 Apr 2026 13:00:00 +0000</pubDate>
				<category><![CDATA[Affordable Care Act]]></category>
		<category><![CDATA[Elections]]></category>
		<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[ACA Marketplaces]]></category>
		<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Federal Budget]]></category>
		<category><![CDATA[Politics]]></category>
		<category><![CDATA[Prior Authorization]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[In a new column, President and CEO Dr. Drew Altman writes about the "conundrum of health policy ideas" facing Democrats searching for new proposals because of competing, and complex, priorities: rebuilding Medicaid and the ACA after trillion-dollar cuts, reconstructing federal health agencies, and tackling underlying health care costs, when candidates want simple ideas they can campaign on and voters want their costs to come down. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">705696</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/BTD-Health-Costs-and-Elections-April-2026_Website.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">BTD-Health Costs and Elections-April 2026_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/BTD-Health-Costs-and-Elections-April-2026_Website.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Public Opinion on Prescription Drugs and Their Prices</title>
		<link>https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/</link>
		
		<dc:creator><![CDATA[kffaeronw]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 12:09:54 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Public Opinion]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Prices]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=poll-findings&amp;p=525491</guid>

					<description><![CDATA[This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">525491</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Public-Opinion-on-Prescription-Drugs-and-Their-Prices-FEATURE.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Public Opinion on Prescription Drugs and Their Prices - FEATURE</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Public-Opinion-on-Prescription-Drugs-and-Their-Prices-FEATURE.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid</title>
		<link>https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/</link>
					<comments>https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/#respond</comments>
		
		<dc:creator><![CDATA[kffmeredithf]]></dc:creator>
		<pubDate>Tue, 24 Mar 2026 19:55:29 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Chronic Diseases]]></category>
		<category><![CDATA[Cost Sharing]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Health and Human Services (HHS)]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare &#38; Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.]]></description>
		
					<wfw:commentRss>https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">705086</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Medicare-and-Medicaid-Gross-Spending-on-GLP-1s-Has-Increased-Substantially-From-2019-to-2024_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Medicare and Medicaid Gross Spending on GLP-1s Has Increased Substantially From 2019 to 2024_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Medicare-and-Medicaid-Gross-Spending-on-GLP-1s-Has-Increased-Substantially-From-2019-to-2024_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>What to Know About Medicare Coverage of Telehealth</title>
		<link>https://www.kff.org/medicare/what-to-know-about-medicare-coverage-of-telehealth/</link>
		
		<dc:creator><![CDATA[kffcarenec]]></dc:creator>
		<pubDate>Thu, 19 Mar 2026 18:23:54 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Access to Care]]></category>
		<category><![CDATA[Administrative Costs]]></category>
		<category><![CDATA[Telehealth]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[Congress has repeatedly extended several pandemic-era flexibilities around Medicare coverage of telehealth, but with a few key exceptions most pandemic-era telehealth flexibilities remain temporary. This brief provides answers to key questions about the current scope of Medicare telehealth coverage, including both temporary and permanent changes adopted through legislation and regulation, and policy considerations that lie ahead.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">638147</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/More-than-1-in-10-Traditional-Medicare-Beneficiaries-Used-Telehealth-in-the-First-Half-of-2025_v2.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">More than 1 in 10 Traditional Medicare Beneficiaries Used Telehealth in the First Half of 2025_v2</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/More-than-1-in-10-Traditional-Medicare-Beneficiaries-Used-Telehealth-in-the-First-Half-of-2025_v2.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Are the Tradeoffs from Prior Authorization Worth It? </title>
		<link>https://www.kff.org/from-drew-altman/are-the-tradeoffs-from-prior-authorization-worth-it/</link>
		
		<dc:creator><![CDATA[kffchrisl]]></dc:creator>
		<pubDate>Mon, 16 Mar 2026 16:39:58 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Private Insurance]]></category>
		<category><![CDATA[Access to Care]]></category>
		<category><![CDATA[Administrative Costs]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Chronic Diseases]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Health Care Utilization]]></category>
		<category><![CDATA[Health System Performance]]></category>
		<category><![CDATA[Managed Care]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[In his latest column, President and CEO Dr. Drew Altman asks if prior authorization review could be eliminated entirely, discussing how it might be done and the tradeoffs.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">704816</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/BTD_Prior-Authorization-Review_March-2026_Website.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">BTD_Prior-Authorization-Review_March-2026_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/BTD_Prior-Authorization-Review_March-2026_Website.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Most Medicare Beneficiaries Affected by Plan Terminations in 2025 Have Robust Medicare Advantage Options in 2026</title>
		<link>https://www.kff.org/medicare/most-medicare-beneficiaries-affected-by-plan-terminations-in-2025-have-robust-medicare-advantage-options-in-2026/</link>
					<comments>https://www.kff.org/medicare/most-medicare-beneficiaries-affected-by-plan-terminations-in-2025-have-robust-medicare-advantage-options-in-2026/#respond</comments>
		
		<dc:creator><![CDATA[kffjeanniefb]]></dc:creator>
		<pubDate>Fri, 13 Mar 2026 14:15:40 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Enrollment]]></category>
		<category><![CDATA[Health Care Markets]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Medigap]]></category>
		<category><![CDATA[Seniors]]></category>
		<category><![CDATA[Traditional Medicare]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=704465</guid>

					<description><![CDATA[Virtually all (98.9%) of the 2.6 million Medicare beneficiaries enrolled in a Medicare Advantage plan that terminated coverage at the end of 2025 have at least one MA-PD available in 2026, including more than two-thirds (68.7%) who have the option of enrolling in a plan sponsored by the same insurer. ]]></description>
		
					<wfw:commentRss>https://www.kff.org/medicare/most-medicare-beneficiaries-affected-by-plan-terminations-in-2025-have-robust-medicare-advantage-options-in-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">704465</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/MA-plan-terminations-analysis_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">MA plan terminations analysis_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/MA-plan-terminations-analysis_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Key Facts About Medicare Drug Price Negotiation</title>
		<link>https://www.kff.org/medicare/key-facts-about-medicare-drug-price-negotiation/</link>
		
		<dc:creator><![CDATA[kffjuliettec]]></dc:creator>
		<pubDate>Wed, 11 Mar 2026 19:25:23 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Prices]]></category>
		<category><![CDATA[Seniors]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=704229</guid>

					<description><![CDATA[Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">704229</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Key-Facts-About-Medicare-Drug-Price-Negotiation.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Key Facts About Medicare Drug Price Negotiation</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Key-Facts-About-Medicare-Drug-Price-Negotiation.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries</title>
		<link>https://www.kff.org/quick-take/what-medicares-temporary-program-covering-glp-1s-for-obesity-means-for-beneficiaries/</link>
		
		<dc:creator><![CDATA[kffaeronw]]></dc:creator>
		<pubDate>Mon, 09 Mar 2026 17:13:19 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Access to Care]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=quick-take&amp;p=704347</guid>

					<description><![CDATA[CMS’s efforts to expand Medicare coverage of GLP-1s for obesity could provide substantial benefits to millions of Medicare beneficiaries, given the potential demand for these highly effective medications…There are potential drawbacks to the short-term program, however.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">704347</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/260309_Quick-Takes_Juliette-Cubanski_Website.jpg?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260309_Quick-Takes_Juliette-Cubanski_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/260309_Quick-Takes_Juliette-Cubanski_Website.jpg?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Analyzing Changes in Medicare Part D Enrollment for 2026</title>
		<link>https://www.kff.org/medicare/analyzing-changes-in-medicare-part-d-enrollment-for-2026/</link>
		
		<dc:creator><![CDATA[kffjuliettec]]></dc:creator>
		<pubDate>Tue, 03 Mar 2026 15:59:46 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Enrollment]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Premiums]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Seniors]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=703933</guid>

					<description><![CDATA[The Medicare Part D prescription drug benefit is provided by private plans, either Medicare Advantage plans that offer drug coverage (MA-PDs) or, for those in traditional Medicare, stand-alone prescription drug plans (PDPs). New data from CMS shows that 56 million people are enrolled in Part D plans as of February 2026, with more in MA-PDs than PDPs, reflecting higher overall enrollment in Medicare Advantage than in traditional Medicare. Enrollment in group MA-PD plans decreased while group PDP enrollment increased.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">703933</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/Medicare-Part-D_56.1-Million-Enrollees-as-of-February-2026_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Medicare Part D_56.1 Million Enrollees as of February 2026_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/Medicare-Part-D_56.1-Million-Enrollees-as-of-February-2026_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Medicare Advantage Enrollment Grew by About 1 Million People, Mainly Due to Special Needs Plans</title>
		<link>https://www.kff.org/medicare/medicare-advantage-enrollment-grew-by-about-1-million-people-mainly-due-to-special-needs-plans/</link>
					<comments>https://www.kff.org/medicare/medicare-advantage-enrollment-grew-by-about-1-million-people-mainly-due-to-special-needs-plans/#respond</comments>
		
		<dc:creator><![CDATA[kffjeanniefb]]></dc:creator>
		<pubDate>Mon, 23 Feb 2026 18:55:24 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Enrollment]]></category>
		<category><![CDATA[Managed Care]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Seniors]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[Just over 35 million people are enrolled in Medicare Advantage in February 2026, an increase of 1.1 million since a year ago. The increase was largely driven by increased enrollment in special needs plans. ]]></description>
		
					<wfw:commentRss>https://www.kff.org/medicare/medicare-advantage-enrollment-grew-by-about-1-million-people-mainly-due-to-special-needs-plans/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">703494</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/total-medicare-advantage-enrollment-2007-2026_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">total-medicare-advantage-enrollment-2007-2026_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/total-medicare-advantage-enrollment-2007-2026_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Health Insurer Financial Performance in 2024</title>
		<link>https://www.kff.org/medicare/health-insurer-financial-performance/</link>
		
		<dc:creator><![CDATA[kffjaredo]]></dc:creator>
		<pubDate>Mon, 23 Feb 2026 13:44:18 +0000</pubDate>
				<category><![CDATA[Affordable Care Act]]></category>
		<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Private Insurance]]></category>
		<category><![CDATA[Employer-Sponsored Health Insurance]]></category>
		<category><![CDATA[Individual Market]]></category>
		<category><![CDATA[Managed Care]]></category>
		<category><![CDATA[Medical Loss Ratio (MLR)]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=issue-brief&amp;p=580406</guid>

					<description><![CDATA[This analysis of trends in health insurers’ financial data shows that insurers’ gross margins per enrollee dipped slightly in 2024 across four markets, remaining highest in the Medicare Advantage market, followed by the individual (non-group) market, the fully insured group (employer) market, and Medicaid managed care. The analysis also examines insurers’ medical-loss ratios across the four markets.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">580406</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/260220_Gross-Margins-are-Highest-in-Medicare-Advantage-in-2024_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260220_Gross-Margins-are-Highest in-Medicare-Advantage-in-2024_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/260220_Gross-Margins-are-Highest-in-Medicare-Advantage-in-2024_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation</title>
		<link>https://www.kff.org/medicare/the-ira-has-improved-coverage-of-drugs-selected-for-medicare-price-negotiation/</link>
		
		<dc:creator><![CDATA[kffjuliettec]]></dc:creator>
		<pubDate>Wed, 11 Feb 2026 18:22:21 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Benefits]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Seniors]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=703022</guid>

					<description><![CDATA[The Medicare drug price negotiation program could improve coverage of drugs selected for negotiation for Medicare beneficiaries because the law requires all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect.
This analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation to measure the effect of the IRA's coverage requirement. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">703022</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">The IRA Coverage Requirement for Selected Drugs Will Improve Access to the GLP-1 Drug Wegovy and Six Other Part D Drugs Selected for Negotiation in Round 2 Starting in 2027_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/The-IRA-Coverage-Requirement-for-Selected-Drugs-Will-Improve-Access-to-the-GLP-1-Drug-Wegovy-and-Six-Other-Part-D-Drugs-Selected-for-Negotiation-in-Round-2-Starting-in-2027_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Examining the Potential Impact of Medicare’s New WISeR Model</title>
		<link>https://www.kff.org/medicare/examining-the-potential-impact-of-medicares-new-wiser-model/</link>
		
		<dc:creator><![CDATA[kffalexc]]></dc:creator>
		<pubDate>Tue, 10 Feb 2026 17:01:48 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Fraud, Waste and Abuse]]></category>
		<category><![CDATA[Prices]]></category>
		<category><![CDATA[Prior Authorization]]></category>
		<category><![CDATA[Traditional Medicare]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=702914</guid>

					<description><![CDATA[On January 1, 2026, the Center for Medicare &#38; Medicaid Innovation (CMMI) launched the Wasteful and Inappropriate Service Reduction (WISeR) Model that establishes new prior authorization requirements in traditional Medicare. This analysis explores the potential impact of the WISeR model by examining recent spending and utilization trends in traditional Medicare for services selected for prior authorization requirements in the six model states (Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington).]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">702914</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/of-the-1.1-million-beneficiaries-who-received-at-least-one-wiser-service-in-2024-over-900-000-received-some-type-of-orthopedic-pain-management-service_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">of-the-1.1-million-beneficiaries-who-received-at-least-one-wiser-service-in-2024-over-900-000-received-some-type-of-orthopedic-pain-management-service_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/02/of-the-1.1-million-beneficiaries-who-received-at-least-one-wiser-service-in-2024-over-900-000-received-some-type-of-orthopedic-pain-management-service_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Recent Trends in GLP-1 Use and Spending in Medicare</title>
		<link>https://www.kff.org/medicare/recent-trends-in-glp-1-use-and-spending-in-medicare/</link>
		
		<dc:creator><![CDATA[kffjuliettec]]></dc:creator>
		<pubDate>Fri, 30 Jan 2026 15:07:26 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=702376</guid>

					<description><![CDATA[Ahead of the Trump administration’s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare’s negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMS’s Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">702376</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/01/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">The Number of GLP-1 Claims in Medicare Part D Increased Four-Fold Between 2019 and 2024, With Claims Doubling Between 2022 and 2024 Alone_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/01/The-Number-of-GLP-1-Claims-in-Medicare-Part-D-Increased-Four-Fold-Between-2019-and-2024-With-Claims-Doubling-Between-2022-and-2024-Alone_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Medicare Advantage Insurers Made Nearly 53 Million Prior Authorization Determinations in 2024</title>
		<link>https://www.kff.org/medicare/medicare-advantage-insurers-made-nearly-53-million-prior-authorization-determinations-in-2024/</link>
		
		<dc:creator><![CDATA[kffmeredithf]]></dc:creator>
		<pubDate>Wed, 28 Jan 2026 16:56:21 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Prior Authorization]]></category>
		<category><![CDATA[Traditional Medicare]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=702020</guid>

					<description><![CDATA[Nearly 53 million prior authorization requests were submitted to Medicare Advantage insurers on behalf of Medicare Advantage enrollees in 2024, of which 4.1 million (7.7%) were denied. Just 11.5% of denied requests were appealed, though 80.7% of appeals overturned the initial denial in Medicare Advantage. Substantially fewer prior authorization requests were made in traditional Medicare, reflecting the small number of services subject to prior authorization requirements.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">702020</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/01/Medicare-Advantage-Insurers-Made-Nearly-53-Million-Prior-Authorization-Determinations-in-2024_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Medicare Advantage Insurers Made Nearly 53 Million Prior Authorization Determinations in 2024_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/01/Medicare-Advantage-Insurers-Made-Nearly-53-Million-Prior-Authorization-Determinations-in-2024_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
	</channel>
</rss>